Piper Jaffray analyst Danielle Brill started GlycoMimetics with an Overweight rating and $20 price target. The shares are undervalued considering the company has two Phase 3 assets in rivipansel and uproleselan with data for the former expected by the end of Q2, Brill tells investors in a research note. Rivipansel aims to reduce duration of sickle cell disease related pain crises and hospitalization times, the analyst points out. She views the drug as a $1.5B opportunity that is not fully priced into the stock. Brill sees "significant upside from two relatively de-risked programs."